GRAIL, Inc. $GRAL Shares Sold by Cwm LLC

Cwm LLC cut its stake in GRAIL, Inc. (NASDAQ:GRAL) by 55.7% in the third quarter, Holdings Channel reports. The fund owned 13,840 shares of the company’s stock after selling 17,399 shares during the period. Cwm LLC’s holdings in GRAIL were worth $818,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Geode Capital Management LLC increased its position in GRAIL by 60.4% during the second quarter. Geode Capital Management LLC now owns 757,770 shares of the company’s stock worth $38,969,000 after purchasing an additional 285,331 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of GRAIL by 7.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 350,979 shares of the company’s stock valued at $18,047,000 after buying an additional 25,548 shares during the period. Invesco Ltd. increased its holdings in shares of GRAIL by 259.1% during the 2nd quarter. Invesco Ltd. now owns 218,671 shares of the company’s stock worth $11,244,000 after buying an additional 157,780 shares during the last quarter. Raymond James Financial Inc. raised its position in shares of GRAIL by 38.2% during the 2nd quarter. Raymond James Financial Inc. now owns 167,433 shares of the company’s stock valued at $8,609,000 after buying an additional 46,264 shares during the period. Finally, Carnegie Investment Counsel acquired a new position in GRAIL in the second quarter valued at approximately $8,520,000.

GRAIL Stock Performance

Shares of GRAL stock opened at $103.59 on Thursday. The stock has a market capitalization of $4.04 billion, a P/E ratio of -8.91 and a beta of 4.52. The company has a 50 day moving average price of $92.35 and a 200 day moving average price of $63.05. GRAIL, Inc. has a fifty-two week low of $16.56 and a fifty-two week high of $115.76.

GRAIL (NASDAQ:GRAL) last released its earnings results on Wednesday, November 12th. The company reported ($2.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.40) by $0.94. The company had revenue of $36.19 million for the quarter, compared to analyst estimates of $33.83 million. GRAIL had a negative net margin of 286.43% and a negative return on equity of 15.69%. On average, research analysts forecast that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Robert P. Ragusa sold 7,239 shares of GRAIL stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $68.88, for a total value of $498,622.32. Following the completion of the transaction, the chief executive officer owned 727,388 shares in the company, valued at approximately $50,102,485.44. This trade represents a 0.99% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Joshua J. Ofman sold 8,865 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $76.03, for a total transaction of $674,005.95. Following the sale, the president owned 387,932 shares in the company, valued at $29,494,469.96. The trade was a 2.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 22,218 shares of company stock valued at $1,674,037. 1.85% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on GRAL shares. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research report on Wednesday, October 8th. Canaccord Genuity Group boosted their price objective on shares of GRAIL from $85.00 to $105.00 and gave the company a “buy” rating in a report on Monday, November 17th. Morgan Stanley upped their target price on shares of GRAIL from $85.00 to $110.00 and gave the company an “equal weight” rating in a research report on Monday, December 1st. Guggenheim raised shares of GRAIL from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a research note on Wednesday, November 12th. Finally, UBS Group set a $75.00 price objective on shares of GRAIL in a report on Friday, October 3rd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $97.50.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.